Inclusion Criteria:
  -  Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
  -  Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
  -  Participants must have an ECOG performance status of less than or equal to 1
  -  Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1
Exclusion Criteria:
  -  Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
  -  Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
  -  Participants must not have a history of allergy to any of the study treatment components